Insulet’s Omnipod 5 System automatically adjusts insulin delivery every five minutes based on blood glucose data from a connected CGM. Image credit: Insulet.

Diabetes patients in the US will have greater flexibility in managing insulin delivery after Insulet announced its Omnipod pump is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor.

The move means the Omnipod 5 is the most connected automatic insulin delivery (AID) system in the US. Shares in Nasdaq-listed Insulet rose 1.75% in premarket trading.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Insulet’s Omnipod 5 System automatically adjusts insulin delivery every five minutes based on blood glucose data from a connected CGM. Insulet’s device, which is already compatible with DexCom’s G6 and G7 CGM devices, is indicated for both type 1 and type 2 diabetes. The company rolled out an app in the US last month to facilitate diabetes management.

This is not the first pump to be paired with Abbott’s FreeStyle Libre 2 Plus, Tandem Diabetes Care’s t:slim X23 device became the first automated insulin delivery system in the US to integrate with it earlier this year.

The added compatibility with Abbott’s FreeStyle Libre 2 Plus will open Insulet’s pump to more of the US diabetes market, estimated to be worth $9.6bn in 2023. By 2033, the market is forecast to grow to around $15.7bn, as per a market model by GlobalData.  

Insulet’s executive vice president and chief product and customer experience officer Eric Benjamin said: “This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod therapy using their preferred CGM sensor.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As of 2021, more than 38 million people have diabetes in the US – around 11.6% of the population in the country. Globally, diabetes prevalence is increasing due to lifestyle changes.

Abbott has the leading market share of CGMs and insulin pens in North America, as per the same analysis by GlobalData. In Q1 2024, Abbott’s FreeStyle Libre sales grew 25.5% to reach $1.5bn. The Plus version is gradually replacing the older FreeStyle Libre 2 sensor across many markets. England’s NHS, for example, said it will make the transition to the newer model by the end of August 2025.

Despite Abbott’s strong performance in the diabetes space this year – its diabetes care segment sales in the US increased by 30% last year compared to 2022 to reach $2.1bn – the company has had to tackle a recall for some models in its CGM line.

The medtech giant recalled FreeStyle Libre 3 sensors after the devices provided incorrect high glucose readings, with the US Food and Drug Administration (FDA) tagging the recall as Class I. Though the FreeStyle Libre 2 was not included in the latest recall, it was involved in an urgent safety notice last year due to a risk of extreme fire and heating risk.